Darden is operating a 2,200-plus-unit full-service restaurant portfolio built around Olive Garden, LongHorn Steakhouse and other differentiated brands, while integrating Chuy’s and shrinking or converting the Bahama Breeze footprint.
The quarter landed exactly where the market expected. Sales rose about 5.1% to $3.20 billion, while adjusted diluted EPS increased 4.1% to $2.05; published expectations were approximately $3.20 billion of revenue and $2.05 of EPS. The result therefore confirms the existing operating story rather than materially improving it.
| Metric | Q1 FY2027 | Q1 FY2026 | Change / comparison |
|---|---|---|---|
| Sales | $3,200.3M | $3,044.7M | +5.1% |
| Adjusted diluted EPS | $2.05 | $1.97 | +4.1% |
| Operating income | $319.3M | $339.2M | -5.9% |
| Net cash from operating activities | $279.0M | $342.5M | -18.5% |
| Repurchases | $222.3M | — | 1.1M shares |
| Quarterly dividend | $1.62/share | — | Declared |
The sales engine held up across the portfolio. Every reported segment posted higher sales and segment profit, with LongHorn the standout: segment profit rose to $154.6 million from $134.9 million, while Olive Garden profit increased only modestly to $270.8 million from $267.6 million. The company said, “The first quarter was a solid start to our fiscal year with each of our segments delivering positive same-restaurant sales,” but the filing does not provide the segment same-restaurant sales percentages. 〔0〕
Margins and cash generation were the weaker part of the quarter. Operating income fell despite higher revenue because food, labor, restaurant, marketing and pre-opening costs all increased; operating expenses rose faster than sales, while net cash from operations dropped to $279.0 million from $342.5 million. The comparison is also affected by last year’s $42.0 million gain on the Olive Garden Canada sale, but even adjusted EPS growth was modest rather than accelerating.
Capital returns remain active, but they are not the new information. Darden declared a $1.62 quarterly dividend and repurchased about $222.3 million of stock during the quarter, leaving $1.3 billion under its $1.5 billion authorization. The company also reaffirmed its fiscal 2027 outlook, so there is no incremental guidance benefit in this release.
Bottom line: Darden executed a broadly healthy but fully expected quarter: demand remained positive, especially at LongHorn, but weaker operating leverage and cash flow keep this from being a meaningful upgrade to the existing story.
Read the original 8-K on SEC EDGAR ↗